Capital International Investors Genmab A/S Transaction History

Capital International Investors

$511 Billion
Q4 2024

A detailed history of Capital International Investors transactions in Genmab A/S stock. As of the latest transaction made, Capital International Investors holds 2,570,909 shares of GMAB stock, worth $57.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,570,909

Previous 4,421,617 41.86%

Holding current value

$57.7 Million

Previous $108 Million 50.23%

% of portfolio

0.01%

Previous 0.02%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$20.02 - $24.15 $37.1 Million - $44.7 Million	-1,850,708 Reduced 41.86%	2,570,909 $53.7 Million
Q3 2024 Nov 13, 2024	BUY	$23.84 - $28.48 $4.62 Million - $5.52 Million	193,652 Added 4.58%	4,421,617 $108 Million
Q2 2024 Aug 13, 2024	SELL	$25.13 - $30.27 $3.65 Million - $4.4 Million	-145,312 Reduced 3.32%	4,227,965 $106 Million
Q1 2024 May 14, 2024	BUY	$26.43 - $32.77 $8.33 Million - $10.3 Million	315,355 Added 7.77%	4,373,277 $131 Million
Q4 2023 Feb 13, 2024	SELL	$27.94 - $35.44 $7.28 Million - $9.23 Million	-260,420 Reduced 6.03%	4,057,922 $129 Million
Q3 2023 Nov 13, 2023	BUY	$35.27 - $42.24 $4.28 Million - $5.12 Million	121,282 Added 2.89%	4,318,342 $152 Million
Q2 2023 Aug 11, 2023	BUY	$37.4 - $42.94 $3.3 Million - $3.79 Million	88,355 Added 2.15%	4,197,060 $160 Million
Q1 2023 May 15, 2023	BUY	$34.88 - $43.22 $2.16 Million - $2.67 Million	61,869 Added 1.53%	4,108,705 $155 Million
Q4 2022 Feb 14, 2023	SELL	$33.8 - $47.06 $27 Million - $37.6 Million	-799,460 Reduced 16.5%	4,046,836 $172 Million
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $4.7 Million - $55.7 Million	149,201 Added 3.18%	4,846,296 $155 Million
Q2 2022 Aug 15, 2022	BUY	$26.83 - $38.57 $20 Million - $28.7 Million	744,649 Added 18.84%	4,697,095 $149 Million
Q1 2022 May 16, 2022	BUY	$30.95 - $39.68 $8.76 Million - $11.2 Million	283,031 Added 7.71%	3,952,446 $145 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $972,794 - $1.28 Million	-27,120 Reduced 0.73%	3,669,415 $146 Million
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $7.04 Million - $8.25 Million	169,379 Added 4.8%	3,696,535 $157 Million
Q2 2021 Aug 16, 2021	BUY	$32.88 - $44.57 $8.57 Million - $11.6 Million	260,648 Added 7.98%	3,527,156 $146 Million
Q1 2021 May 14, 2021	BUY	$30.92 - $44.4 $11.3 Million - $16.2 Million	365,464 Added 12.6%	3,266,508 $104 Million
Q4 2020 Feb 12, 2021	BUY	$33.66 - $40.76 $12.3 Million - $14.9 Million	366,152 Added 14.44%	2,901,044 $118 Million
Q3 2020 Nov 13, 2020	SELL	$33.07 - $38.68 $2.15 Million - $2.52 Million	-65,032 Reduced 2.5%	2,534,892 $94.6 Million
Q2 2020 Aug 14, 2020	BUY	$20.05 - $33.89 $52.1 Million - $88.1 Million	2,599,924 New	2,599,924 $84.9 Million

Others Institutions Holding GMAB

# of Institutions

246

Shares Held

61.3M

Call Options Held

159K

Put Options Held

38K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital International Investors with notifications on news.

Account

Capital International Investors Genmab A/S Transaction History